GSE185200 GSE185202 L-13 Ali-BL 0 v 9 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE185200_GSE185202_L-13_Ali-BL_0_v_9_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE185200_GSE185202_L-13_Ali-BL_0_v_9_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE185200_GSE185202_L-13_Ali-BL_0_v_9_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE185200_GSE185202_L-13_Ali-BL_0_v_9_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

ribosomal protein S18

Gene

growth arrest specific 5

Gene

small nucleolar RNA host gene 29

Gene

H3.3 histone A

Gene

differentiation antagonizing non-protein coding RNA

Gene

small nucleolar RNA host gene 4

Gene

DPY19L2 pseudogene 2

Gene

GIHCG inhibitor of miR-200b/200a/429 expression

Gene

negative regulator of antiviral response

Gene

small integral membrane protein 48

  • Gene

    ribosomal protein S18


  • Gene

    growth arrest specific 5


  • Gene

    small nucleolar RNA host gene 29



  • Gene

    differentiation antagonizing non-protein coding RNA


  • Gene

    small nucleolar RNA host gene 4


  • Gene

    DPY19L2 pseudogene 2


  • Gene

    GIHCG inhibitor of miR-200b/200a/429 expression


  • Gene

    negative regulator of antiviral response


  • Gene

    small integral membrane protein 48

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.